Editas Medicine (EDIT) Q1 2025 Earnings
Editas Medicine reported Q1 2025 revenue of $4.7M (+310.4% YoY), beat analyst consensus of $706.1K by $4.0M. Diluted EPS came in at $-0.43 (+43.4% YoY), beat the $-0.51 consensus by $0.08.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Editas Medicine's Q1 2025 earnings report.
Editas Medicine (EDIT) reported Q1 2025 earnings on May 12, 2025 after market close.
Editas Medicine reported revenue of $4.7M and diluted EPS of $-0.43 for Q1 2025.
Revenue beat the consensus estimate of $706.1K by $4.0M. EPS beat the consensus estimate of $-0.51 by $0.08.
Compared to the same quarter a year prior, revenue grew 310.4% from $1.1M a year earlier and diluted EPS grew 43.4% from $-0.76.
You can read the 10-Q periodic report (0001650664-25-000073) directly on SEC EDGAR. The filing index links above go to sec.gov.